Home
FDA Calendar
About & More
Testimonials
Useful Links
Our Disclaimer
Updates and Roadmap
Contribute
Create Company Profile
Create Drug Profile
Browse
Contact
FDA Calendar for Applied NeuroSolutions Inc. (APSN.OB)
Login Now
|
Register (free)
Applied NeuroSolutions, Inc. (APNS) is a development-stage biopharmaceutical company primarily engaged in the research and development of therapeutic targets for the treatment of Alzheimer's disease (AD) and diagnostics to detect AD. The Company’s core technology in the AD field is based on licenses with Albert Einstein College of Medicine (AECOM) covering all diagnostic and therapeutic applications in the field of neurodegenerative disease. The Company also works on both a cerebrospinal fluid (CSF)-based test and serum-based tests to detect AD at an early stage. In a research setting, its CSF-based test, which detects a certain AD associated protein found in the CSF of AD patients (P-Tau 231), has demonstrated an ability to differentiate AD patients from those with other diseases that have similar symptoms. In a research setting, its CSF-based test has demonstrated an ability to differentiate AD patients from those with other diseases that have similar symptoms.
Around The Net
Latest News
Twitter Stream
Yahoo Message Board
Google Message Board
You are reading news provided by a variety of web sources.
Drug Pipeline
Drug Name
Type Of Drug
FDA Status
Drug Phase
This company currently does not have any drugs. If you would like to create one please
click here
.
Events
No future events listed at this time, please check back later.
Outcome
Past Events
Add New Event
In order to write a comment you must first login.
Login
or
Register
(for free!)
Add Event
Important Links
No links found.
Add New Link
In order to write a comment you must first login.
Login
or
Register
(for free!)
Add Link
$0.00
0
1/1/0001 12:00:00 AM
Sponsors
Other Links
Corporate Website
Analyst Estimates (MarketWatch)
CNN Money
Google Finance
Guru Focus
Major Holders
MSN Money
SEC Filings (EDGAR Online)
Seeking Alpha
Yahoo! Finance